Go to the list of all blogs
Rick Johnson's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Why Is Keros Therapeutics (KROS) Stock Up 6.58% Today?

Why Is Keros Therapeutics (KROS) Stock Up 6.58% Today?

Key Takeaways

  • Keros Therapeutics (KROS) shares gained 6.58%, or $0.66, to $10.69 in Tuesday morning trading, up from Monday's close of $10.03.
  • The primary catalyst was a new $5 million share repurchase authorization, approved by the board after the company collected a $20 million Takeda development milestone for elritercept.
  • A secondary driver was a BofA price-target increase to $18 from $17, with the firm maintaining a Neutral rating following third-quarter results.
  • The advance extends a rebound from $8.98 on November 10, a 52-week low, after shares fell 12.7% on November 6 despite a large quarterly earnings beat.
  • Context matters: the stock is still down roughly 51% year to date and trades below its 50-session average of about $11.
  • News Significance Score: 38/100 — Modest capital-return news amplified by a move roughly three times the stock's normal daily swing.
  • Traders are watching whether KROS holds above the $10 level, whether the buyback is actually executed, and the first rinvatercept Duchenne data expected in the first half of 2027.
  • Readers can dig deeper into Price Targets, Earnings, and Forecast pages for additional detail on the name.
  • Explore Trending AI Robots to see which automated strategies are currently performing best.

Opening Summary

Keros Therapeutics (KROS) is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, developing protein therapeutics that target dysfunctional signaling within the TGF-β family — pathways that regulate muscle, bone, fat, heart tissue and blood. Its most advanced asset, elritercept, is licensed to Takeda for development in cytopenias associated with myelodysplastic syndromes and myelofibrosis, while its lead wholly owned candidate, rinvatercept, is aimed at Duchenne muscular dystrophy and ALS.

Shares traded at $10.69 in Tuesday's session, a gain of 6.58% from the prior close of $10.03. The direction was firmly positive, with the move following a pair of verified disclosures: a new share repurchase authorization announced after Monday's close and an analyst price-target revision published Monday morning.

New Buyback Tied to a $20 Million Takeda Milestone

The clearest catalyst arrived late Monday, when the company said its board approved a new program to repurchase up to $5 million of common stock. The authorization followed receipt of a $20 million development milestone under the elritercept license with Takeda Pharmaceuticals U.S.A., triggered by dosing of the first patient in the ELRiSE MF clinical trial in myelofibrosis.

Two things about the disclosure matter to investors. First, the $20 million milestone is fresh cash equal to roughly a tenth of the company's market value. Second, management is directing part of it toward shareholders rather than spending it all on development. Keros reported $259.5 million of cash and equivalents at September 30 and now projects that, after the milestone and the repurchase, funding will carry operations and capital spending into 2029 — an extension from the second half of 2028 previously guided. Importantly, the program carries no obligation to buy a specific number of shares and can be suspended at any time, which tempers the signal.

Analyst Price Target Revision

BofA Securities raised its price target on Keros to $18 from $17 and reiterated a Neutral rating, updating its model after the third-quarter report. The revision is supportive but incremental — it lifts the implied upside without changing the firm's stance, and it followed a quarter that produced a spectacular headline beat.

Rebound From a 52-Week Low

The move is also a recovery trade. On November 5 the company reported third-quarter revenue of $40.0 million and GAAP earnings of $0.70 per share, both far above consensus, yet the stock plunged 12.7% the next session as investors focused on the non-recurring nature of license revenue and the absence of product sales. Selling continued to $8.98 on November 10, a 52-week low and the floor of the 52-week range of $8.97 to $22.41. Buyers have stepped in since, lifting shares 19% off that low even before Tuesday's advance.

Market Context and Trading Activity

Early-session turnover looked light relative to the stock's three-month average daily volume of roughly 187,000 shares, suggesting the gain reflected a thinning order book rather than a large institutional accumulation. The stock is a micro-cap with a market value near $200 million and close to 1.1 million shares sold short, about 5.5% of the float — enough for short covering to amplify headline-driven moves.

Technically, the advance is repairing damage but has not reversed the trend. Keros remains below its 50-session average of approximately $11.02 and well below the $11.95 October peak. A close above $11 would mark the first meaningful higher close in a month; a failure there keeps the September-to-November downtrend intact. The gap left by the November 6 selloff around $10.83 is the nearest overhead obstacle.

News Significance Score

The score runs from 0 to 100, where 0 means no meaningful news and a normal move, and 100 means transformative news and an extreme, rare price move. Keros earns 38 out of 100.

The verified news was moderate rather than major: $25 million of combined cash inflow and buyback capacity is material for a company of this size, but the repurchase is discretionary and no clinical data changed hands. The price move was roughly three times the stock's typical daily absolute change of about 2.2%, and a move this large occurred only twice in the past 60 sessions. Modest news and a moderately unusual move combine into a below-midpoint score.

What Comes Next for KROS

The next hard catalyst is initial Phase 2 data for rinvatercept in Duchenne muscular dystrophy, guided for the first half of 2027, alongside regulatory discussions on a planned ALS study. Fourth-quarter and full-year 2026 results are expected in early 2027, in line with the company's recent reporting cadence, and seven covering analysts hold a consensus Buy rating with an average target near $20.

Risks cut both ways. Elritercept economics now sit largely with Takeda, so Keros depends on milestones and royalties rather than product revenue, and license income will be lumpy and non-repeating. Clinical timelines in neuromuscular disease slip frequently, and the company still burns cash. Watch whether management actually executes buybacks, since unexercised authorizations have limited effect on the share count.

Trending AI Robots

Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions appear in the curated Trending AI Robots section. The bots differ by strategy, timeframe, performance metrics and the symbols they trade, so the lineup shifts as market conditions change. Reviewing the current leaders is a practical way to see which approaches are working right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: KROS

KROS sees its Stochastic Oscillator ascending out of oversold territory

On November 13, 2026, the Stochastic Oscillator for KROS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 55 instances where the indicator left the oversold zone. In 49 of the 55 cases the stock moved higher in the following days. This puts the odds of a move higher at over 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where KROS's RSI Indicator exited the oversold zone, 31 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.

Following a +7.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 224 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

KROS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KROS as a result. In 68 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.

The Moving Average Convergence Divergence Histogram (MACD) for KROS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 33 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.

KROS moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for KROS crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 59%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.

The Aroon Indicator for KROS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.707) is normal, around the industry mean (3.586). P/E Ratio (-2.907) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. KROS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -10%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -22%. PEPG experienced the highest price growth at 75%, while ALGS experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on treatments for rare muscle diseases

Industry Biotechnology

Industry
N/A
Address
1050 Waltham Street
Phone
+1 617 314-6297
Employees
78
Web
https://www.kerostx.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.